Covid-19

#Covid-19 #CRISPR #Genetic editing

Stanford engineers develop a genetic microlab to detect COVID-19 in minutes

By Andrew Myers Throughout the pandemic, infectious disease experts and frontline medical workers have asked for a faster, cheaper and more reliable COVID-19 test. Now, leveraging the so-called “lab on a chip” technology and the cutting-edge genetic editing technique known as CRISPR, researchers at Stanford have created a highly automated… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Drug repositioning

Beta-blockers could be used to treat COVID-19, says study

University of South Australia cancer researcher, Dr Nirmal Robinson, working with a team in Naples, has found evidence in animal models that the beta-blocker Propranolol helps suppress the spread of cancer in the lung which has an inflammatory profile very similar to COVID-19. The scientists have presented their findings in… Read More

#Covid-19 #News

#Antibodies #Covid-19

Method finds COVID-19 monoclonal antibody among a trillion possibilities

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralising human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method– as well as a trio of successful animal studies on an antibody called ‘Ab1’– are described today in the Proceedings of the… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Analysis shows difference of up to three months in current COVID-19 vaccine trial recruitment

Analysis from virtual clinical development specialist Phesi shows the enrolment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrolment, however, looking deeper, there is a significant difference in the Site Effectiveness Index… Read More

#Covid-19 #News

#Biomarkers #Covid-19 #Metabolomics

Study identifies biomarkers that could be used in a quick, inexpensive COVID-19 screening tool

A new study from Lawson Health Research Institute, Western University and University of Alberta suggests that COVID-19 affects the human body’s blood concentration levels of specific metabolites – small molecules broken down in the human body through the process of metabolism. Three specific metabolites identified in this study could act… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Novel candidates #Therapeutics

Novel COVID-19 antibody therapy candidates identified by UK biotech consortium

The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody ‘cocktail’. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna agreement to supply Qatar with mRNA COVID-19 vaccine

Moderna has announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19. “We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date,” said Stéphane Bancel, Moderna’s Chief… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine follows genetic instructions, analysis finds

The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) has been shown to work as planned. A team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team. This novel analysis… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Global clinical trials of COVID-19 vaccine resume

The Food and Drug Administration (FDA) has today authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the USA following the trials restarting in the UK, Brazil, South Africa and Japan. On 6 September, a standard review process triggered a voluntary pause to vaccination across… Read More

#Covid-19 #Editor's Choice #News

#Assay development optimisation & technology #Covid-19 #Therapeutics

PerkinElmer immunoassay helps identify therapeutic compounds to tackle COVID-19

A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer’s AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics. The NCATS research project is focused on studying small molecule drug compounds that… Read More

#Covid-19 #News

#Covid-19 #Drug development #Therapeutics

Aerogen collaborates on development of COVID-19 inhaled therapies

Aerogen has released details of a collaborative effort to support global pharmaceutical companies developing COVID-19 vaccines and therapies. To date, more than ten million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology. As the global scientific community rallies against the pandemic, there has been interest… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

UK government signs deal to help speed up COVID-19 vaccine

hVIVO, has signed a contract with the UK government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. The contract starts immediately and could be worth approximately £10 million to hVIVO –… Read More

#Covid-19 #News

#Antibodies #Clinical trials #Covid-19

NIH study aims to identify promising COVID-19 treatments for larger clinical trials

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial,… Read More

#Covid-19 #News

#Cold chain #Covid-19 #Immunology / Virology & Vaccines

Keeping the cold chain unbroken for COVID research and vaccine development

Robin Vacha, Senior Vice President, Products at Brooks Life Sciences and David Lewandowski, Global Business Development Manager, Cryo Division at Brooks Life Sciences examine the role of unbroken cold chain in research and development As COVID-19 vaccine research continues to grow at an unparalleled pace, so does the need for… Read More

#Covid-19 #Exclusive Content